Nobilis Health Corp.
NRTSF
$0.00
$0.000.00%
| Weiss Ratings | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | -- | |||
| Risk Index | -- | |||
| Risk Grade | -- | |||
| Reward Grade | -- | |||
| Rating Factors | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | -- | |||
| Efficiency Index | -- | |||
| Solvency Index | -- | |||
| Total Return Index | -- | |||
| Volatility Index | -- | |||
| Beta / Standard Deviation | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -28.72 | |||
| Price History | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -99.00% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -99.00% | |||
| 5-Year Total Return | -99.98% | |||
| 52-Week High % Change | -99.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Mar 14, 2024 | |||
| 52-Week High Price (Date) | Aug 02, 2024 | |||
| Valuation | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 78.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 713-355-8614 | |||
| Address | 11700 Katy Freeway Houston, TX 77079 | |||
| Website | www.nobilishealth.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 7.00% | |||
| Profit Margin | 0.58% | |||
| Management Effectiveness | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.40% | |||
| Return on Equity | 4.31% | |||
| Income Statement | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 272.53M | |||
| Total Revenue (TTM) | 281.67M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 172.21M | |||
| EBITDA (TTM) | 36.05M | |||
| EBIT (TTM) | 19.74M | |||
| Net Income (TTM) | 1.64M | |||
| Net Income Avl. to Common (TTM) | 1.64M | |||
| Total Revenue Growth (Q YOY) | -13.47% | |||
| Earnings Growth (Q YOY) | -46.54% | |||
| EPS Diluted (TTM) | 0.02 | |||
| EPS Diluted Growth (Q YOY) | -43.50% | |||
| Balance Sheet | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 16.53M | |||
| Cash Per Share (Q) | $0.20 | |||
| Total Current Assets (Q) | 177.95M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 205.49M | |||
| Current Ratio (Q) | 2.211 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 80.48M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | 149.52M | |||
| Cash Flow | NRTSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -57.38M | |||
| Cash from Financing (TTM) | 33.87M | |||
| Net Change in Cash (TTM) | -12.69M | |||
| Levered Free Cash Flow (TTM) | -827.90K | |||
| Cash from Operations (TTM) | 10.82M | |||
